BioSpace News Archive

Pharmaceutical industry is progressing at a rapid rate to cover the various diseases that affect human beings.

The osteoporosis drugs market has been anticipated to grow at a significant speed in the forthcoming years.

Avenge Bio, Inc., (“Avenge” or the “Company”) today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth this week at the 14th Annual Next Generation Dx Summit.

FIGUR8, the digital health company that’s developed the most advanced musculoskeletal (MSK) health evaluation solution on the market, announced today that the American Medical Association (AMA) has issued a new technology-specific Category III Current Procedural Terminology (CPT®) code for FIGUR8’s musculoskeletal technology.

The National Institute of Allergy and Infectious Disease (NIAID) awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes Hepatitis C, an illness that affects an estimated 71 million people worldwide.

Stryker (NYSE:SYK) will participate in the 2022 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2022.

Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant’s pipeline candidate OPNT004 (drinabant) for the treatment of cannabinoid hyperemesis syndrome (CHS), a condition among cannabis users that leads to repeated and severe bouts of vomiting.

BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended June 30, 2022.

Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, sent a letter to Rubric Capital Management LP responding to a letter from Rubric dated August 19, 2022, in which Rubric purported to call for a General Meeting of Shareholders of Mereo and proposed to remove four of Mereo’s directors and replace them with four directors nominated by Rubric.